
Aillis
An AI-powered medical device for early and accurate influenza detection.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor | €0.0 | round |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | $3.3m Valuation: $56.7m | Series D | |
Total Funding | 000k |
Related Content
Aillis is a Japanese company focused on developing artificial intelligence-powered medical devices. The firm's flagship product is "nodoca," a device designed for the diagnosis of influenza. This system utilizes a specialized camera to capture images of a patient's pharynx (throat) and combines this visual data with other information, such as body temperature, for analysis.
The core of nodoca is its AI algorithm, which examines the pharyngeal images to identify signs of influenza, aiming to replicate the diagnostic skills of experienced physicians. This approach offers a non-invasive method for influenza testing, providing a digital alternative to conventional diagnostic procedures.
The company operates in the MedTech and digital health sectors, targeting healthcare providers like hospitals and clinics as its primary clients. Its business model is centered on the development and provision of this specialized diagnostic tool to medical professionals, contributing to the field of AI-driven medical diagnostics.
Keywords: AI, medical device, influenza, diagnostics, MedTech, healthcare, image analysis, non-invasive, digital health, pharyngeal imaging